Technical Analysis for CTOR - Citius Oncology, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.98 | -1.42% | -0.01 |
CTOR closed down 1.42 percent on Thursday, November 21, 2024, on 25 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -1.42% | |
| NR7-2 | Range Contraction | -1.42% | |
| Narrow Range Bar | Range Contraction | -1.42% |
| Alert | Time |
|---|---|
| Possible NR7 | about 5 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| Up 3% | about 10 hours ago |
| Down 2 % | about 10 hours ago |
| Down 1% | about 10 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Citius Oncology will serve as a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals.
Keywords: FDA Oncology Therapies
Classification
Keywords: FDA Oncology Therapies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 49.0 |
| 52 Week Low | 0.932 |
| Average Volume | 141,548 |
| 200-Day Moving Average | 8.07 |
| 50-Day Moving Average | 1.25 |
| 20-Day Moving Average | 1.15 |
| 10-Day Moving Average | 1.12 |
| Average True Range | 0.17 |
| RSI (14) | 37.50 |
| ADX | 7.61 |
| +DI | 18.52 |
| -DI | 23.41 |
| Chandelier Exit (Long, 3 ATRs) | 0.93 |
| Chandelier Exit (Short, 3 ATRs) | 1.45 |
| Upper Bollinger Bands | 1.37 |
| Lower Bollinger Band | 0.92 |
| Percent B (%b) | 0.12 |
| BandWidth | 39.39 |
| MACD Line | -0.13 |
| MACD Signal Line | -0.14 |
| MACD Histogram | 0.0081 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.06 | ||||
| Resistance 3 (R3) | 1.06 | 1.04 | 1.04 | ||
| Resistance 2 (R2) | 1.04 | 1.02 | 1.04 | 1.04 | |
| Resistance 1 (R1) | 1.01 | 1.01 | 1.00 | 1.00 | 1.03 |
| Pivot Point | 0.99 | 0.99 | 0.98 | 0.98 | 0.99 |
| Support 1 (S1) | 0.95 | 0.97 | 0.94 | 0.95 | 0.92 |
| Support 2 (S2) | 0.93 | 0.95 | 0.93 | 0.91 | |
| Support 3 (S3) | 0.90 | 0.93 | 0.91 | ||
| Support 4 (S4) | 0.90 |
